Introduction
Chronic inflammatory pain is a recurrent disorder, affecting approximately at 20% of world population, and the actual therapies (nonsteroidal anti-inflammatory drugs, opioids, etc) may be limited in scope, have dose-limiting side effects. That reflects the need to search new strategies to treat more effectively this type of pain.
The transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) regulates two important cytoprotective pathways: the anti-oxidative and the anti-inflammatory (Kim et al., 2010) . A crucial factor for the antioxidant activity of Nrf2 is the regulation of the antioxidant response element (ARE) found in the promoter regions of numerous genes that encode antioxidant and detoxification enzymes, for example heme oxygenase 1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), superoxide dismutase 1, etc. which maintain the homeostatic equilibrium by regulating the reactive oxygen species (ROS) cumulating. Recent investigations also demonstrated that Nrf2 activation, in addition to modulating oxidative stress, it's also able to directly inhibit the transcription of cytokines (interleukin (IL)-1, IL-6) by an independent mechanism of ARE and ROS levels (Kobayashi et al., 2016) . Therefore, while the lack of Nrf2 augmented the inflammatory response in the joints and the expression of the tumor necrosis factor- (TNF) and IL-6 accelerating the arthritis signs (Maicas et al., 2011) , its activation reduced inflammation by decreasing the synthesis of several pro-inflammatory mediators, like the inducible isoform of nitric oxide synthase (NOS2), cyclooxygenase-2, IL-1, IL-6, and the mitogen-activated protein kinase (MAPK) in the cartilage from osteoarthritic animals (Kim et al., 2009; Davidson et al., 2013) . More interesting is the result that the activation of Nrf2 also reduced acute pain provoked by nitroglycerin and neuropathic pain associated to diabetes or generated by nerve-injury in rodents (Negi et al, 2011; Di et al. 2016; McDonnell et al., 2017; Wang and Wang, 2017) . Nevertheless, the role played by Nrf2 on the allodynia and hyperalgesia induced by chronic peripheral inflammation has not been studied.
We and other authors have demonstrated that treatment with HO-1 inducer compounds, like the cobalt protoporphyrin IX (CoPP), besides to inhibit chronic pain also potentiated the This article has not been copyedited and formatted. The final version may differ from this version.
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5 antinociceptive properties of µ-opioid receptor (MOR) agonists during neuropathic and inflammatory pain (Hervera et al., 2013a; 2013b; Carcolé et al., 2014) . On the basis of these results, we postulated that Nrf2 induction could also plays an important role on the modulation of the antinociceptive effects of morphine (a MOR agonist) in animals with chronic inflammatory pain.
It is well known that activated microglia is implicated in the progress of inflammatory and neuropathic pain (Martini et al., 2016) by mediating the synthesis of abundant inflammatory mediators (TNF, IL, NOS2, etc) and its inhibition reduced allodynia and hyperalgesia in animals with chronic pain (Pol, 2007; Hervera et al., 2012; Mika et al., 2013) . In addition, MAPK also exercises a crucial role in the regulation of inflammatory reactions. That is, during inflammatory pain c-Jun NH2-terminal kinase (JNK), extracellular signal regulated kinase (ERK1/2) and p38 MAPK are differentially activated in neurons and glial cells and its inhibition attenuates pain (Gao and Ji, 2008; Ji et al., 2009 ). Nevertheless, the role played by sulforaphane (SFN), a Nrf2 inducer compound, in the modulation of these inflammatory mediators in mice with chronic inflammatory pain is still unknown.
In a complete Freund's adjuvant (CFA) induced chronic inflammatory pain in mice we assessed the: 1) antiallodynic and antihyperalgesic effects of the repetitive intraperitoneal administration of 5 and 10 mg/kg of SFN; 2) antinociceptive effects of the administration of SFN in combination with a subanalgesic dose of morphine; 3) effects of SFN on the expression of Nrf2, HO-1, NQO1, NOS2, CD11b/c (microglial marker), MOR and MAPK (JNK, ERK1/2 and p38) activation in the spinal cord and paw of CFA-injected mice.
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Materials and Methods
Experimental animals. For experimental procedures, male C57BL/6 mice acquired in Envigo (Barcelona, Spain) were employed. The weight of all mice was between 21 to 25 g. Mice were accommodated under 12-h/12-h light/ dark conditions in a room with controlled temperature of 22º C and humidity of 66 %. Animals with free access to food and water were used after a minimum of 7 days acclimatization to the housing conditions. All experiments were executed according with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health and approved by the local Committee of Animal Use and Care of the Autonomous University of Barcelona. Maximal exertions to reduce animal suffering and number of animals employed were made.
Induction of chronic inflammatory pain. We induced chronic inflammatory pain with the subplantar injection of CFA (30 µl; Sigma-Aldrich, St. Louis, MO) into the right hind paw under brief anesthetic conditions with isoflurane according to our other studies (Leánez et al., 2009; Hervera et al., 2009) . Mechanical allodynia was measured by means of the von Frey filaments and thermal hyperalgesia with the plantar test. Animals were checked in both behavioral tests before and at 3, 4, 7, 10 and 14 days after CFA-injection.
Nociceptive behavioral tests. Mechanical allodynia was measured by evaluating the hind paw withdrawal response to von Frey filament stimulation. Mice were sited in methacrylate cylinders of 20 cm (high) x 9 cm (diameter) (Servei Estació, Barcelona, Spain) on a wire grid bottom across which the von Frey filaments (North Coast Medical, Inc., San Jose, CA) with a bending force in the range of 0.008-3.5 g were applied by employing an adapted version of the up-down paradigm described by Chaplan et al. (1994) . We start the test with the filament of 0.4 g and the filament of 3.0 g was utilized as a cut-off. The strength of next filament was increased or decreased in accordance to the answer. Threshold of response was calculated from the sequence of filament strength used during the up-down procedure using an Excel program (Microsoft Iberia SRL, Barcelona, Spain) which includes curve fitting of the data. A clear paw This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on September 25, 2017 as DOI: 10.1124 at ASPET Journals on October 18, 2017 jpet.aspetjournals.org Downloaded from JPET #244376 7 withdrawal, lick or shaking the paw was considered to be a nociceptive-like response. Both ipsilateral and contralateral hind paws were tested. Thermal hyperalgesia was evaluated by evaluating paw withdrawal latency in response to radiant heat by using the plantar test apparatus (Ugo Basile, Varese, Italy) and in accordance to the method proposed by Hargreaves et al. (1988) . Mice were placed in methacrylate cylinders of 20 cm (high) x 9 cm (diameter) situated on a glass surface. The heat source was positioned under the plantar surface of each of both hind paws (contralateral and ipsilateral) and activated with a light beam intensity selected in previous works with baseline latencies from 8 to 10 s under control conditions. To avoid tissue damage in lack of response, a cut-off time of 12 s was established. The mean paw withdrawal latencies were calculated from the average of 3 distinct trials, taken at 5 min pauses to avoid thermal sensitization and behavioral disturbances.
In all of these nociceptive behavioral assays, mice were habituated to the test for 1 h before testing to obtain a suitable behavioral immobility and they were performed by a male experimenter blinded to the treatments applied.
Western blot analysis. Animals were sacrificed by cervical dislocation at 0 (naïve) and 14 days after CFA injection from SFN or vehicle treated mice. Tissues from the ipsilateral side of the lumbar section of the spinal cord or hindpaw were extracted quickly after killing, frozen in liquid nitrogen and maintained at 80°C until use. For all tissues, samples from four animals were pooled together to have the adequate levels of proteins for doing Western blot assay. The protein levels of Nrf2, HO-1, NQO1, NOS2, CD11/bc, MOR and MAPK (pJNK/JNK, pERK1/2/ERK1/2, pp38/p38) were analyzed. The homogenization of tissues was performed in ice-cold lysis buffer (50 mM Tris·Base, 150 nM NaCl, 1% NP-40, 2 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 0.5 Triton X-100, 0.1% sodium dodecyl sulfate, 1 mM Na3VO4, 25 mM NaF, 0.5 % protease inhibitor cocktail, and 1% phosphatase inhibitor cocktail). Except NP-40 that was purchased from Calbiochem (Darmstadt, Germany), all other reagents were acquired at Sigma (St. Louis, MO). After solubilisation of crude homogenate for 1 h at 4ºC, it was sonicated during 10 s and centrifuged at 4°C for 15 min at 700 g. Then, the supernatant (60 Chalfont, Buckinghamshire, United Kingdom) was used to detect proteins which were visualized with chemiluminescence reagents (ECL kit; GE Healthcare) and by exposure onto hyperfilm (GE Healthcare). Blots intensity was quantified by densitometry. Stripped membranes were reproved with a rabbit anti-glyceraldehyde-3-phosphate dehydrogenase antibody (GAPDH) (1:5000, Merck, Billerica, MA, USA) utilized as a loading control.
Experimental procedure. Baseline responses were established after the habituation period, beginning with the von Frey filaments followed by plantar test. After paw inflammation induction, animals were once again tested in each test at days 3, 4, 7, 10 and 14 after CFA injection as for baseline measures by using the same sequence. We used contralateral paws as controls (n = 6 animals for group). CFA-injected mice were administered with 5 and 10 mg/kg of SFN, an Nrf2 transcription factor activator, or vehicle (DMSO 1% solution in saline) during 11 consecutive days, from day 4 to 14 after CFA-injection.
In a second set of studies, we evaluated the mechanical antiallodynic and thermal antihyperalgesic effects produced by 10 mg/kg of SFN intraperitoneally administered alone and in combination with a subanalgesic dose of morphine (50 µg) subplantarly injected in the right hindpaw. Both, contralateral and ipsilateral paws of CFA injected animals were tested (n = 6 animals for group). The dose of SFN used for the combination was obtained from this study and the dose of morphine was selected from a previous work (Carcolé et al., 2014) , as the one that displayed a minimal antinociceptive effect. Researcher performing these experiments was blinded to the treatments applied.
The protein levels of Nrf2, HO-1, NQO1, NOS2, CD11b/c, MOR and MAPK (p-JNK/total JNK, pERK1/2/total ERK1/2, pp38/total p38) in the ipsilateral site of spinal cord and paw from mice with peripheral inflammation and treated with SFN o vehicle, were also evaluated by Western blot assay. Naïve mice treated with vehicle were utilized as controls (n = 4 samples for group). For mechanical allodynia, the subplantar administration of CFA significantly decreased the threshold for evoking hind paw withdrawal to a mechanical stimulus. This effect was clearly observed after 3 days of CFA injection, and it is maintained until day 14 in the ipsilateral paw of vehicle treated animals when compared to its respective contralateral paw (P < 0.001; one way ANOVA; Fig. 1A ). The three way ANOVA repeated measure showed a significant effect of the paw, treatment and time (P <0.001) and the interactions between paw and treatment (P <0.001), treatment and time (P <0.001), paw and time (P <0.001) and between paw, treatment and time (P <0.001). Consequently, mechanical allodynia was significantly attenuated in mice daily treated with 5 and 10 mg/kg of SFN during 11 days (P < 0.001, one-way ANOVA, compared to the ipsilateral paw of CFA-injected mice treated with vehicle; Fig. 1A ). But while mechanical allodynia was equally reduced with the administration of 5 and 10 mg/kg of SFN on day 1 of treatment, the antiallodynic effects produced by 10 mg/kg of SFN after 7 days of treatment were higher than those obtained by the small dose (P < 0.001, one-way ANOVA). Moreover, although the antiallodynic effects produced by both doses increased progressively from days 1 to 7 of treatment (P < 0.001, one-way ANOVA, vs to the ipsilateral paw of CFA-injected mice treated with vehicle), while mechanical allodynia was completely reversed at 7 days of treatment (10 days after CFA injection) with 10 mg/kg of SFN, 11 days of treatment with 5 mg/kg are needed to obtain this effect.
Peripheral inflammation also produced a significant decrease of the threshold for evoking ipsilateral paw withdrawal to a thermal stimulus in vehicle treated mice from days 3 to 14 after CFA injection as compared to their corresponding contralateral paws (P < 0.001, one-way Fig 1B) . The effects of the intraperitoneal administration of SFN at 5 and 10 mg/kg have been also evaluated. The three-way ANOVA repeated measures showed a significant effect of the paw, treatment and time (P <0.001) as well as the interaction between paw and treatment (P <0.001), treatment and time (P <0.001), paw and time (p<0.001) and among paw, treatment and time (P <0.001) (Fig 1B) . Our results showed that thermal hyperalgesia caused by CFA was progressively attenuated after the daily treatment with SFN (5 and 10 mg/kg), but similar to that occurs with the mechanical allodynia, the complete reversion of thermal hyperalgesia was achieved at 7 and 11 days of treatment with 10 or 5 mg/kg of SFN, respectively (P < 0.001, one-way ANOVA, in comparison to the ipsilateral paw of mice with peripheral inflammation treated with vehicle). Data demonstrated that whereas the intraperitoneal administration of SFN or morphine administered alone did not produce significant antiallodynic ( Fig. 2A) and antihyperalgesic ( Fig. 2B) effects as compared to those produced by vehicle. SFN treatment significantly improved the mechanical antiallodynic ( Fig. 2A ) and thermal antihyperalgesic effects (Fig. 2B) produced by morphine locally administered in the ipsilateral paw of CFA-injected mice (P <0.001, one-way ANOVA, versus vehicle group treated with saline or morphine, or with SFN administered alone). The local administration of morphine alone or combined with SFN did not have any effect on the contralateral paw of CFA-injected animals, neither for mechanical allodynia (Fig. 2C ) nor for thermal hyperalgesia (Fig. 2D) . (Fig. 3) and paw (Fig. 4) from CFA-injected mice treated during 11 days with 10 mg/kg of SFN or vehicle, and from naïve mice receiving vehicle were evaluated. Indeed, while the diminished expression of Nrf2 in the spinal cord from CFA-injected mice (P <0.01, one-way ANOVA when compared to naïve mice treated with vehicle) was normalized by treatment with SFN (P <0.01, one-way ANOVA versus CFA-injected mice treated with vehicle) (Fig. 3A) . A significant increased expression of Nrf2 induced by SFN was demonstrated in the paw from mice with peripheral inflammation (P <0.01, one-way ANOVA versus naïve and CFA-injected mice treated with vehicle) (Fig. 4A ). Regarding HO-1, while peripheral inflammation increased the spinal cord levels of this enzyme (P <0.001, one-way ANOVA versus naïve vehicle treated mice) (Fig. 3B) , non-statistically significant alterations in its expression in the paw from CFAinjected mice was detected (Fig. 4B) . Nevertheless, SFN treatment increased HO-1 protein levels in both tissues (P <0.001, one-way ANOVA versus naïve and CFA-injected mice treated with vehicle). Our findings also showed that SFN treatment enhanced the expression of NQO1 enzyme in the spinal cord (Fig. 3C) and paw (Fig. 4C ) as compared to naïve and CFA-injected mice treated with vehicle (P <0.01, one-way ANOVA). Moreover, while peripheral inflammation did not modify the spinal cord levels of NOS2 (Fig 3E) , a significant overexpression of this enzyme was observed in the paw (P <0.004, one-way ANOVA versus naïve treated with vehicle) (Fig 4E) , which was significantly reversed by SFN administration. In addition, whereas the unaltered MOR levels observed in the spinal cord (Fig. 3F) and paw ( Fig.   4F ) from CFA injected mice remain intact with SFN treatment in the spinal cord, a significant augmented expression of MOR was revealed in the paw tissues from SFN treated animals (P < 0.028 one-way ANOVA versus naïve and CFA-injected mice treated with vehicle). Finally, the spinal microglial activation caused by peripheral inflammation (P < 0.002 one-way ANOVA versus naïve mice treated with vehicle) was totally reversed with SFN treatment (P < 0.002 oneway ANOVA versus CFA-injected mice treated with vehicle) (Fig. 3G) . (Fig. 5A) and paw (Fig. 6A ) from CFA-injected mice (P < 0.05 one-way ANOVA, versus naïve mice treated with vehicle) were significantly diminished by SFN treatment in both tissues (P < 0.05 one-way ANOVA versus CFA-injected mice treated with vehicle). Regarding ERK1/2, while non-changes in its expression was observed in the spinal cord (Fig. 5B) , treatment with SFN prevented its activation in the paw from CFA-injected mice (P < 0.005 one-way ANOVA, versus CFAinjected mice treated with vehicle) (Fig. 6B) . Lastly, the spinal cord activation of p38 induced by inflammation (Fig. 5C ) was as well significantly reduced in SFN treated mice (P < 0.028 one-way ANOVA versus CFA-injected mice treated with vehicle), while non-significant changes in the expression of pp38 were observed in the paw from CFA-injected mice (Fig. 6C) . Several studies demonstrated that the transcription factor Nrf2, furthermore to its antioxidant and neuroprotective effects, also plays an important role on the modulation of inflammation (Kobayashi et al., 2016) . Therefore, loss or disruption of Nrf2 signaling causes an increased susceptibility to oxidative stress as well as to inflammatory tissue injuries (Kim et al., 2010) .
Effects of acute treatment with

Effects of repeated treatment with SFN on the
Other works also shown the antinociceptive effects elicited by substances capable to activate the transcription factor Nrf2 during acute inflammatory pain (Rosa et al., 2008) and in neuropathic pain associated to type 1 and 2 diabetes (Negi et al., 2011; McDonnell et al., 2017) . In this work we demonstrated that treatment with SFN (a Nrf2 activator) also decreased the mechanical and thermal hypersensitivity induced by chronic peripheral inflammation, in a dose-dependent manner. That is, whereas 7 days of SFN treatment at 10 mg/kg are needed to inhibit inflammatory pain, 11 days of the continuous administration of this drug at 5 mg/kg are required. These data supported the preceding reports and furthermore demonstrated the antiallodynic and antihyperalgesic actions of SFN in chronic inflammatory pain in mice.
Our findings also proved that the administration of SFN avoided the reduced levels of Nrf2 in the spinal cord and enhanced its expression in the paw tissues from animals with inflammatory pain. This treatment also enhanced the down-stream enzymes activated by Nrf2, such as HO-1 and NQO1 in both tissues suggesting that the antiallodynic and antihyperalgesic effects produced by SFN during inflammatory pain might be in part produced by its antioxidant activity mediated by the induction of these antioxidant enzymes. Supporting our results, the 
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antinociceptive role played by the activation of HO-1 in inflammatory and neuropathic pain conditions have been also described (Hervera et al., 2012 (Hervera et al., , 2013b Carcolé et al., 2014) . SFN treatment reduced the increased expression of NOS2 in the paw from CFA-injected mice. These data agree with the diminished NOS2 expression identified in the sciatic nerve from animals with diabetic neuropathy or nerve-injury induced neuropathic pain treated with SFN (Negi et al., 2011; Wang and Wang, 2017) , as well as with HO-1 inducers (Castany et al., 2016) and further demonstrated the negative regulatory role played by Nrf2 on the expression of NOS2 under inflammatory pain conditions. It is also well known the involvement of microglia in the development of chronic pain. Using the expression of CD11b/c, as a microglial marker, our data reveals significant microglial activation in the spinal cord of animals with peripheral inflammation, which was reversed by SFN treatment. Therefore and considering the antinociceptive effects produced by specific microglial inhibitors in animals with chronic pain (Mika et al., 2009; , the alleviation of inflammatory pain induced by SFN might have also in part due by inhibiting spinal microglial activation.
In order to evaluate if the inhibition of MAPK activated by inflammatory pain is also involved in the effects produced by SFN, we investigated the expression of phosphorylated JNK, ERK1/2 and p38 in the spinal cord and paw tissues from mice treated with SFN. It is well known that the activation of JNK executes an important role in the development and maintenance of chronic pain (Middlemas et al., 2006; Gao and Ji, 2008) ERK1/2 is another member of MAPK which phosphorylated form also increased in response to several stimulus (inflammation, nerve injury, diabetes) at different levels of pain processing pathway (Borges et al., 2015) . Our data demonstrated that the augmented expression of pERK1/2 in the paw from mice with chronic inflammatory pain was significantly reduced by SFN treatment. In accordance to us, a significant activation of pERK1/2 was also identified in the dorsal root ganglia from animal with acute and chronic peripheral inflammation (Cheng et al., 2008; Cheng and Keast, 2009; Gao and Ji, 2010) . Since the administration of specific ERK1/2 inhibitors diminished the nociceptive response induced by inflammatory pain, the fact that SFN inhibited ERK phosphorylation in the paw also supports the hypothesis that the antinociceptive effects of this Nrf2 inductor during chronic inflammatory pain might also be mediated via inhibition pERK1/2 in the paw. Finally, p38 activation is also responsible for the peripheral inflammation induced hyperalgesia (Ji et al., 2002; Hudmon, et al., 2008) and of the up-regulation of numerous inflammatory mediators in the spinal cord (Svensson et al., 2003) .
Accordingly, a significant increased levels of pp38 was detected in the spinal cord from CFAinjected mice, that was completely blocked with the SFN treatment revealing that the effectivity of this treatment against chronic inflammatory pain also include the modulation of p38 phosphorylation in the spinal cord of these animals. Finally, although we only assessed the effects of the systemic administration of SFN on the spinal cord and paw from animals with peripheral inflammation, it's probable that this treatment also produces relevant effects in other areas, such as the dorsal root ganglia, as occurs with other related treatments, for example with the administration of HO-1 activators in mice with chronic pain (Hervera et al., 2012; Carcolé et al., 2014; Castany et al., 2016) .
Our study demonstrated that the small antinociceptive effects produced by the local administration of a low dose of morphine during peripheral inflammation were significantly improved by SFN treatment. These results expanded our previous data indicating that the activation of HO-1 with CoPP potentiated the peripheral antinociceptive actions of morphine in animals with inflammatory and neuropathic pain caused by nerve-injury or associated to diabetes (Hervera et al., 2013a; Carcolé et al., 2014; Castany et al., 2016) and further revealed 
